Our findings underscore the cytoprotective effects of pharmacologically enhancing Nrf2 transcriptional efficiency, which directly bind to promoter region and upregulate Hspb1 expression, thereby blocking ferroptosis and offering a novel avenue for therapeutic intervention in PD. The gene discussed is HSPB1; the disease is Parkinson disease.